At some point in the future, an individual’s genome will be a foundational part of their medical record. Driving towards precision medicine involves increasingly comprehensive sequencing and arrays, access to standardized testing, integration into systems used by health care providers to manage patients, and building evidence that genomic information has clinical utility and can be used to improve outcomes. Sustainable incorporation of genomics into routine care requires efficient testing, readily accessible genomic data and decision support, and data aggregation that can assess patient outcomes. In this session, various stakeholders, including both healthcare (large, integrated healthcare systems), healthcare information technology, and insurance providers, will share their perspectives on current approaches and the challenges they observe on achieving this goal.
Dr. Phil G. Febbo is responsible for developing and executing the Company’s medical strategy to drive genomic testing into healthcare practice. Dr. Febbo has a successful track record of translational research, clinical excellence, and for embedding molecular insights into clinical care. Immediately before joining Illumina, Dr. Febbo served as CMO of Genomic Health for five years where he drove the company’s medical strategy, was accountable for the team management and development of evidence supporting GHI’s proprietary tests and engaged with the payer community to drive reimbursement. Prior to his five years at Genomic Health, Dr. Febbo was a Professor of Medicine and Urology at the University of California, San Francisco (UCSF), where his laboratory focused on using genomics to understand the biology and clinical behavior of prostate cancer, and his clinical practice focused on genitourinary oncology. Dr. Febbo currently serves on the board of the American College of Medical Genetics and Genomics Foundation.